Loading
A phase 3 trial of Cadonilimab, Sugemalimab in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.
A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC is a phase 3 interventional study registered as NCT06617416 by Akeso, with 560 participants planned, started 2024-11-12 and due to reach its primary completion in 2026-10-28. Interventions recorded: Cadonilimab (AK104), Sugemalimab. Conditions listed: NSCLC (Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Small-cell lung cancer.
Shares Akeso, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Akeso, Bispecific antibodies, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Bispecific antibodies, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/